Good morning, you're listening to Markets Desk.
Oil is the macro story you cannot ignore right now. Brent crude is sitting at one hundred sixteen dollars and ten cents a barrel as of this morning, up more than a dollar forty from yesterday and roughly fifty three dollars higher than where it stood a year ago. That kind of year-over-year move reshapes inflation expectations, pressures transport costs, and complicates the Fed's calculus considerably.
Staying in the healthcare space, a gold-standard clinical trial is adding serious weight to the GLP-one thesis that has driven names like Novo Nordisk for years. Semaglutide, the active compound in Ozempic and Wegovy, was found to meaningfully reduce heavy drinking in patients with alcohol-use disorder. That expands the addressable market for these drugs well beyond obesity and diabetes, which is exactly the kind of pipeline broadening that long-term investors in this sector have been watching for.
And rounding out the session, preferred stocks are drawing renewed attention as income-hungry investors search for yield in a high-rate environment. These hybrid securities, sitting between common equity and bonds in the capital structure, are currently offering yields approaching ten percent in some cases, and many are trading at a discount to par, meaning buyers are getting both income and potential price appreciation.
That's the tape. Markets Desk, signing off the floor.
